1. Home
  2. KNDI vs VTGN Comparison

KNDI vs VTGN Comparison

Compare KNDI & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kandi Technologies Group Inc

KNDI

Kandi Technologies Group Inc

HOLD

Current Price

$0.56

Market Cap

61.9M

ML Signal

HOLD

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.26

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNDI
VTGN
Founded
2002
1998
Country
China
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.9M
10.8M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
KNDI
VTGN
Price
$0.56
$0.26
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$0.90
AVG Volume (30 Days)
73.7K
397.8K
Earning Date
04-28-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$124.49
Revenue Next Year
N/A
$353.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.20
52 Week High
$1.35
$5.14

Technical Indicators

Market Signals
Indicator
KNDI
VTGN
Relative Strength Index (RSI) N/A 48.49
Support Level N/A $0.23
Resistance Level N/A $0.32
Average True Range (ATR) 0.00 0.01
MACD 0.00 0.00
Stochastic Oscillator 0.00 61.73

Price Performance

Historical Comparison
KNDI
VTGN

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: